Zelluna ASA [ZLNA]: Notification of transaction by close associate of primary insider

26 Mar 2025 13:55 CET

Oslo, Norway, 26 March, 2025

Reference is made to the stock exchange notice published by Zelluna ASA (the
"Company") published on 26 March 2025 regarding the resolution by the Company's
board of directors to carry out a share capital increase of NOK 0.70 through the
issuance of seven (7) new shares in the Company in order to achieve a desirable
ratio for the reverse share split.

The Company has received the following notification of a transaction made by a
close associate of a primary insider:

* Radforsk Investeringsstiftelse, a close associate of chair of the board of
directors and primary insider of the Company, Anders Tuv, has today
subscribed for seven (7) new shares in the Company at a subscription price
of NOK 2.60 (equal to the price per share in the recently completed business
combination and private placement). Following this transaction, Radforsk
Investeringsstiftelse hold 24,714,221 shares in Zelluna ASA.

The notification concerning the above subscription is attached hereto.

For further information, please contact:

Hans Vassgård Eid, CFO, Zelluna ASA
Email: hans.eid@zelluna.com (mailto:[%20hans.eid@zelluna.com])
Phone: +47 482 48632

About Zelluna ASA
Zelluna's mission is to deliver transformative treatments with the capacity to
cure advanced solid cancers, in a safe and cost-efficient manner, to patients on
a global scale. The Company aims to do this by combining the most powerful
elements of the immune system through pioneering the development of "off the
shelf" T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK).
The TCR-NK platform offers a unique mechanism of action with broad cancer
detection capability to overcome the diversity of tumours and will be used "off
the shelf" to overcome scaling limitations of current cell therapies. The lead
program is a world's first MAGE-A4 targeting "off the shelf" TCR-NK for the
treatment of various solid cancers; a pipeline of earlier products follows. The
Company is led by a management team of biotech entrepreneurs with deep
experience in discovery through to clinical development of TCR and cell-based
therapies including marketed products.

More information:
Access the news on Oslo Bors NewsWeb site

642269_Zelluna ASA - PDMR attachment.pdf